Living with a pouch
The pouchitis that comes back when the antibiotics stop
Antibiotics clear it, and it returns within days of the last dose. That pattern has a name, an American guideline behind it, and a set of trade-offs worth understanding before the next prescription.
4 min read5 sources
An ileoanal pouch is built from the end of the small bowel, and the most common thing that goes wrong with it is inflammation of the pouch itself. The American Gastroenterological Association’s guideline puts the figure at 48 percent of people within the first two years after the operation, with up to 80 percent developing symptoms of pouchitis at some point. Approximately 17 percent go on to develop chronic symptoms.
The usual first treatment is an antibiotic, and it usually works. What comes next is harder to prepare for: of the people whose acute pouchitis responds to that first course, a review of antibiotics in inflammatory bowel disease reports that approximately 60 percent have at least one recurrence.
Sorted by what happens when you stop
Gastroenterology sorts pouchitis not by how bad it looks but by how the inflammation behaves when the drug is withdrawn. Bo Shen and Bret Lashner set out the three categories still in use today — antibiotic-responsive, antibiotic-dependent and antibiotic-refractory. Responsive is the good outcome: the course clears it and it stays cleared. The other two are worth telling apart: they are easily confused, and the guideline treats them as different problems with different answers.
Antibiotic-dependent
- the antibiotic works
- symptoms relapse shortly after it stops, typically within days to weeks
- the guideline suggests chronic antibiotic therapy, or advanced immunosuppressive therapy
Antibiotic-refractory
- the antibiotic does not work
- symptoms are relapsing-remitting or continuous, with inadequate response to typical antibiotic therapy
- the guideline suggests advanced immunosuppressive therapies
The word carrying the weight in the middle category is dependent, and it is worth being exact about it. What returns when the drug is withdrawn is the inflammation. It describes how a disease behaves, not the person swallowing the tablets, and it does not mean anybody has become addicted to an antibiotic.
The number the guideline would not set
You might reasonably expect a threshold — four episodes in a year, or six, some count that tips you from one category into the next. The American guideline considered that and declined. In its own words, it did not define this entity based on a specific number of pouchitis episodes within a 12-month time period. What defines it is the timing of the relapse against the last dose, not a tally of episodes.
What the guideline suggests
The 2024 guideline was the first comprehensive one published on pouchitis, and it issued nine recommendations, every one of them conditional. For an isolated episode it suggests ciprofloxacin or metronidazole, typically for two to four weeks. For people whose pouchitis keeps recurring but keeps responding, it suggests chronic antibiotic therapy, and advanced immunosuppressive therapies for that same group. After a course it suggests a multi-strain probiotic to prevent recurrence, and it suggests against antibiotics to prevent a first episode.
What staying on them costs
The guideline sets the case for long-term antibiotics against what long-term antibiotics do, and is explicit about the list:
- antimicrobial resistance, and becoming colonised with drug-resistant organisms
- Clostridioides difficile infection, which people with inflammatory bowel disease are already at increased risk of
- peripheral neuropathy with metronidazole, which one review describes as possibly permanent if the drug is used for prolonged intervals
- tendinopathy with ciprofloxacin, alongside tendon rupture, photosensitivity and QT prolongation
There are numbers attached. The guideline cites adverse event rates of ciprofloxacin at 1 per 10,000 use-days and metronidazole at 6 per 10,000 use-days. The review reports metronidazole side effects in 10 to 50 percent of people according to dose and length of therapy — gastrointestinal intolerance, neurotoxicity and a metallic taste — with up to a third ceasing treatment because of them.
Why this is a conversation and not a decision
Bo Shen, Section Head and Medical Director of the Inflammatory Bowel Disease Center at NewYork-Presbyterian and Columbia University Irving Medical Center, is blunt about how much variation hides under the one word. Pouchitis, he says, is actually a spectrum of some 30 to 40 disorders that vary in etiology, pathogenesis, phenotype and clinical course. Although initial acute episodes typically respond to antibiotic therapy, patients can become dependent on antibiotics or develop refractory disease.
Where this came from
48 percent of people within the first two years after IPAA and up to 80 percent at some point, with approximately 17 percent developing chronic symptoms; the definitions of chronic antibiotic-dependent and chronic antibiotic-refractory pouchitis, including relapse within days to weeks; the refusal to define the entity by a number of episodes within a 12-month period; nine conditional recommendations; ciprofloxacin or metronidazole for a typical two to four weeks; chronic antibiotic therapy and advanced immunosuppressive therapies for antibiotic-dependent pouchitis, conditional and on very low certainty of evidence; immunosuppressive therapy for antibiotic-refractory pouchitis; probiotics to prevent recurrence; against antibiotics for primary prevention; the risks of long-term antibiotic use and the adverse event rates of 1 and 6 per 10,000 use-days.
Barnes EL, Agrawal M, Syal G, Ananthakrishnan AN, Cohen BL, Haydek JP, Al Kazzi ES, Eisenstein S, Hashash JG, Sultan SS, Raffals LE, Singh S; AGA Clinical Guidelines Committee, “AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders”, Gastroenterology, 2024;166(1):59–85That this was the first comprehensive medical guideline published on the management of pouchitis.
American Gastroenterological Association, “First comprehensive medical guideline on management of pouchitis released”, press release, 2023Approximately 60 percent of people whose acute pouchitis responds to antibiotics have at least one recurrence; metronidazole side effects in 10 to 50 percent according to dose and length of therapy, with up to a third ceasing therapy through intolerance, and possible permanent peripheral neuropathy with prolonged use; the ciprofloxacin side effect list; the increased risk of Clostridium difficile infection in inflammatory bowel disease.
Nitzan O, Elias M, Peretz A, Saliba W, “Role of antibiotics for treatment of inflammatory bowel disease”, World Journal of Gastroenterology, 2016;22(3):1078–1087The classification of pouchitis as antibiotic-responsive, antibiotic-dependent or antibiotic-refractory; that overuse of antibiotics may shift the microflora responsible for pouchitis from conventional to nonconventional forms such as C. difficile, fungi or parasites.
Shen B, Lashner BA, “Diagnosis and Treatment of Pouchitis”, Gastroenterology & Hepatology (New York), 2008;4(5):355–361Bo Shen’s title and institution; that pouchitis is a spectrum of some 30 to 40 disorders varying in etiology, pathogenesis, phenotype and clinical course; that although initial acute episodes typically respond to antibiotic therapy, patients can become dependent on antibiotics or develop refractory disease.
NewYork-Presbyterian, “Dr. Bo Shen: Leading the Way in IBD and Pouch Disorders”, Advances in Gastroenterology and GI Surgery